Open AccessThromboembolic complications of hormonal therapy in women. Position of cardiologist
Author(s) -
И. А. Горлова,
M. Yu. Omelchenko,
Л. А. Соколова,
Б. Б. Бондаренко
Publication year - 2020
Publication title -
translâcionnaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2410-5155
pISSN - 2311-4495
DOI - 10.18705/2311-4495-2020-7-4-6-11
Subject(s) - medicine , estrogen , progestin , menopause , hormonal therapy , hormone , hormone therapy , population , endometrial hyperplasia , genitourinary system , gynecology , intensive care medicine , obstetrics , endometrium , breast cancer , cancer , environmental health
Thromboembolic complications is a frequent cause of acute cardiovascular events, disability and mortality. Among the factors that increase their risk in the female population using of medications, containing sex hormones is of high significance. In oral contraceptives the main — contraceptive activity belongs to gestagen, while estrogen performs an auxiliary function of menstrual cycle control. In medications used for therapy during menopause the main active substance is estrogen. Progestin provides prevention of endometrial hyperplasia. Despite the intensive search for optimal effective and safe schemes of combined hormonal drugs, the risk of thrombotic complications in patients using them both for therapeutic purposes and as contraception remains high. The article provides clinical observations illustrating the administration of hormonal therapy to women is reasonable to be discussed and agreed with cardiologists and/or general practitioners, and the patients would be informed about possible cardiovascular complications of such therapy for an adequate selfcontrol.